ML261
Phase 1Biologic
ML261 is one of 11 biologic programs targeting Small Cell Lung Cancer ( SCLC ). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Small Cell Lung Cancer ( SCLC )
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Vepesid
AAvyxa
Phase 3
Obrixtamig
Boehringer IngelheimPhase 3
Taxol
TevaPreclinical
Zepzelca
Jazz PharmaceuticalsPreclinical
Camptosar
PfizerPreclinical
Hycamtin
MMeitheal
Preclinical
PF-08634404
PfizerPreclinical
ML261
MMoonlight Bio, Inc
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer ( SCLC )1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ML261. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- MMoonlight Bio, Inc